GPP
CLYM

Great Point Partners’s Climb Bio CLYM Stock Holding History

Great Point Partners’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13M Sell
1,000,000
-334,130
-25% -$3.45M 2.46% 17
2026
Q1 		$9.14M Buy
1,334,130
+354,596
+36% +$2.05M 2.1% 18
2025
Q4 		$3.92M Buy
+979,534
New +$2.35M 1.27% 25
2024
Q4 		– Sell
-248,168
Closed -$1.26M – 34
2024
Q3 		$1.26M Buy
+248,168
New +$1.76M 0.37% 30

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Great Point Partners's CLYM Position: Q2 2026 in Review

Great Point Partners reduced its Climb Bio (CLYM) stake by 25% in Q2 2026, selling an estimated $3.45M and leaving 1,000,000 shares worth $13M. The position accounts for 2.46% of the portfolio, ranked #17.

Great Point Partners first reported a position in CLYM in Q3 2024 and has held it in 4 quarters since. 109 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

  • Great Point Partners held 1,000,000 shares of Climb Bio worth $13M as of Q2 2026.
  • Great Point Partners sold 334,130 Climb Bio shares in Q2 2026, an estimated $3.45M.
  • Climb Bio made up 2.46% of Great Point Partners's portfolio in Q2 2026, its #17 holding.
  • Great Point Partners first reported a position in Climb Bio in Q3 2024 and has held it in 4 quarters since.
  • 109 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on Great Point Partners's 13F filing for Q2 2026, filed 14 Aug 2026.